Compounds > delavirdine
Page last updated: 2024-08-16

delavirdine and nevirapine

delavirdine has been researched along with nevirapine in 127 studies

Research

Studies (127)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's29 (22.83)18.2507
2000's51 (40.16)29.6817
2010's46 (36.22)24.3611
2020's1 (0.79)2.80

Authors

AuthorsStudies
Althaus, IW; Biles, C; Busso, M; Genin, MJ; Morge, RA; Resnick, L; Reusser, F; Romero, DL; Tarpley, WG; Thomas, RC1
Adams, WJ; Biles, C; Evans, DB; Friis, JM; Hosley, JD; Keiser, BJ; Kopta, LA; Morge, RA; Morris, J; Olmsted, RA; Poel, TJ; Romero, DL; Sharma, SK; Stefanski, KJ; Stehle, RG; Tarpley, WG; Thomas, RC; Voorman, RL; Wishka, DG; Yagi, Y1
Barringer, KJ; Brickwood, JR; Cywin, CL; David, E; Erickson, DA; Grob, PM; Hattox, SE; Hoermann, M; Joseph, DP; Klunder, JM; Pauletti, D; Schwartz, R; Shih, CK; Sorge, CL1
Mao, C; Sudbeck, EA; Uckun, FM; Venkatachalam, TK2
Maher, D; Mao, C; Pendergrass, S; Tuel-Ahlgren, L; Uckun, FM; Venkatachalam, TK; Zhu, D2
Bäckbro, K; Engelhardt, P; Fridborg, K; Högberg, M; Johansson, NG; Kangasmetsä, J; Lövgren, S; Noréen, R; Oberg, B; Sahlberg, BL; Sahlberg, C; Unge, T; Vrang, L; Zhang, H1
Artico, M; De Montis, F; La Colla, P; Marceddu, T; Massa, S; Silvestri, R1
Anderson, PS; Bacheler, LT; Corbett, JW; Cordova, BC; Diamond, S; Erickson-Viitanen, SK; Garber, S; Gearhart, LA; Jeffrey, S; Klabe, RM; Ko, SS; Logue, K; Magnus, NA; Rodgers, JD; Trainor, GL1
Andries, K; Arnold, E; Azijn, H; Daeyaert, FF; Das, K; de Béthune, MP; De Corte, BL; de Jonge, MR; Heeres, J; Ho, CY; Janssen, PA; Kavash, RW; Koymans, LM; Kukla, MJ; Lewi, PJ; Lichtenstein, MA; Ludovici, DW; Pauwels, R; Van Aken, KJ; Ye, H1
Andries, K; Benjahad, A; Grierson, DS; Guillemont, J; Nguyen, CH1
Andrews, CW; Boone, LR; Chan, JH; Cowan, JR; Creech, KL; Ferris, RG; Freeman, GA; Gonzales, SS; Hazen, RJ; Koszalka, GW; Lowell, GS; Reynolds, DJ; Roberts, GB; Romines, KR; Schaller, LT; Short, SA; St Clair, M; Tidwell, JH; Weaver, K1
Andries, K; Arnold, E; Boyer, PL; Clark, AD; Clark, P; Daeyaert, F; Das, K; De Béthune, MP; De Corte, B; De Jonge, MR; Heeres, J; Ho, CY; Hughes, SH; Janssen, PA; Kavash, RW; Koymans, LM; Kukla, MJ; Lewi, PJ; Lichtenstein, MA; Ludovici, DW; Pauwels, R; Vinkers, HM; Ye, H1
Andrews Iii, CW; Boone, LR; Chan, JH; Cowan, JR; Creech, KL; Ferris, RG; Freeman, GA; Gonzales, SS; Hazen, RJ; Hopkins, AL; Koszalka, GW; Lowell, GS; Milton, J; Ren, J; Reynolds, DJ; Roberts, GB; Schaller, LT; Short, SA; Stammers, DK; Stuart, DI; Weaver, K1
De Corte, BL1
Andries, K; Arnold, E; Bettens, E; Daeyaert, FF; Das, K; de Béthune, MP; de Jonge, MR; Gaurrand, S; Guillemont, J; Heeres, J; Hertogs, K; Janssen, PA; Koymans, LM; Lewi, PJ; Palandjian, P; Pasquier, E; Pauwels, R; Timmerman, P; Vernier, D; Vinkers, MH; Wigerinck, P1
Kang, X; Kollman, PA; Kuntz, ID; Wang, J1
Haefeli, WE; Ketabi-Kiyanvash, N; Lindenmaier, H; Theile, D; Weiss, J1
Bettens, E; Demestre, C; Guillemont, J; Heeres, J; Hertogs, K; Lewi, P; Masungi, C; Mordant, C; Pasquier, E; Peeters, A; Queguiner, L; Schmitt, B; Smeulders, L1
Andricopulo, AD; Moda, TL; Montanari, CA1
Artursson, P; Bergström, CA; Draheim, R; Holmén, AG; Wassvik, CM1
Andrews, CW; Boone, L; Chamberlain, PP; Chan, JH; Ferris, RG; Freeman, A; Hazen, R; Ren, J; Romines, KR; Short, SA; Stammers, DK; Stamp, A; Weaver, KL1
Cao, Y; De Clercq, E; Liu, X; Pannecouque, C; Wang, Y; Zhan, P1
Armanasco, N; Azijn, H; de Bethune, MP; Fletcher, P; Harman, S; Manlow, P; Nuttall, J; Perumal, D; Romano, J; Shattock, R1
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E1
Bachmann, MH; Fessel, WJ; Kagan, RM; Mitsuya, Y; Shafer, RW; Shahriar, R; Varghese, V1
De Clercq, E; Fang, Z; Li, Z; Liu, X; Pannecouque, C; Zhan, P1
Clercq, ED; Fang, Z; Li, Z; Liu, X; Pannecouque, C; Zhan, P; Zhu, J1
Fransen, S; Gupta, S; Huang, W; Paxinos, EE; Petropoulos, CJ; Stawiski, E1
Balzarini, J; Chen, FE; De Clercq, E; Feng, XQ; Liang, YH; Pannecouque, C; Zeng, ZS1
Balzarini, J; Chen, FE; Clercq, ED; Feng, XQ; He, QQ; Liang, YH; Liu, ZQ; Pannecouque, C; Zeng, ZS1
Balzarini, J; Chen, FE; De Clercq, E; Feng, XQ; He, QQ; Liang, YH; Pannecouque, C; Zeng, ZS1
Corbau, R; Fishburn, L; Irving, S; Knöchel, T; Martin, A; Mori, J; Mowbray, C; Panton, W; Perros, M; Phillips, C; Ringrose, H; Smith-Burchnell, C; Thornberry, A; Westby, M; Wood, A1
Haefeli, WE; Weiss, J; Zembruski, NC1
De Clercq, E; Ge, W; Jiang, Y; Li, Z; Liu, X; Pannecouque, C; Wu, J; Zhan, P; Zhang, J1
Balzarini, J; Chen, FE; De Clercq, E; Gu, SX; He, QQ; Ma, XD; Pannecouque, C; Yang, SQ1
Balzarini, J; Chen, FE; Clercq, ED; Dai, HF; Gu, SX; He, QQ; Ma, XD; Pannecouque, C; Yang, SQ1
Balzarini, J; Chen, FE; De Clercq, E; Gu, SX; He, QQ; Li, ZM; Ma, XD; Pannecouque, C; Yang, SQ1
Balzarini, J; Chen, X; De Clercq, E; Li, D; Li, X; Liu, H; Liu, X; Pannecouque, C; Wang, L; Zhan, P1
Chen, W; Chen, X; De Clercq, E; Li, X; Li, Z; Liu, X; Pannecouque, C; Tian, Y; Zhan, P1
Chen, W; Chen, X; Clercq, ED; Li, X; Li, Z; Liu, X; Pannecouque, C; Tian, Y; Zhan, P1
Briñón, MC; Daelemans, D; Dehaen, W; Leen, V; Madrid, M; Pannecouque, C; Ribone, SR1
Balzarini, J; De Clercq, E; Li, D; Liu, H; Liu, X; Pannecouque, C; Zhan, P1
Chen, FE; Daelemans, D; De Clercq, E; Liu, Y; Ma, XD; Pannecouque, C; Yang, S1
Balzarini, J; Chen, FE; Chen, WX; Daelemans, D; De Clercq, E; He, QQ; Pannecouque, C; Wu, HQ; Yan, ZH1
Balzarini, J; Chen, X; De Clercq, E; Li, Z; Liu, H; Liu, X; Pannecouque, C; Xie, Z; Zhan, P; Zhang, L; Zhao, T1
Balzarini, J; Chen, W; De Clercq, E; Liu, H; Liu, X; Pannecouque, C; Rai, D; Zhan, P; Zhou, Z1
De Clercq, E; Li, Z; Liu, H; Liu, X; Pannecouque, C; Wang, J; Zhan, P1
De Clercq, E; Du, D; Liu, H; Liu, X; Pannecouque, C; Rai, D; Tian, Y; Wang, L; Zhan, P1
Chen, FE; Chen, WX; De Clercq, E; He, QQ; Huang, XY; Pannecouque, C; Wu, HQ; Yan, ZH1
Chen, FE; Chen, WX; De Clercq, E; He, QQ; Pannecouque, C; Piao, HR; Wu, HQ; Wu, Y; Yan, ZH1
Balzarini, J; Chen, F; Chen, W; De Clercq, E; Liu, Y; Meng, G; Pannecouque, C; Zheng, A1
Chen, W; De Clercq, E; Li, D; Liu, H; Liu, X; Pannecouque, C; Tian, Y; Wang, L; Zhan, P1
Balzarini, J; Chen, W; De Clercq, E; Li, X; Liu, H; Liu, X; Lu, X; Pannecouque, C; Zhan, P1
Ariën, KK; Augustyns, K; Cos, P; Dirié, B; Heeres, J; Joossens, J; Lewi, PJ; Lyssens, S; Maes, L; Michiels, J; Van der Veken, P; Vanham, G; Venkatraj, M1
Chen, FE; Chen, WX; Daelemans, D; De Clercq, E; He, QQ; Pannecouque, C; Wu, HQ; Yao, J1
Chen, FE; Daelemans, D; De Clercq, E; Lu, YP; Mao, TQ; Pannecouque, C; Tao, Y; Wan, ZY; Wang, HF; Wang, XL; Wu, Y; Yao, J; Yin, H1
Chen, FE; Daelemans, D; De Clercq, E; Mao, TQ; Pannecouque, C; Piao, HR; Tao, Y; Wan, ZY; Wang, YF; Yin, H1
De Clercq, E; Li, W; Li, X; Liu, X; Zhan, P1
Chen, W; Daelemans, D; De Clercq, E; Huang, B; Kang, D; Li, X; Liu, X; Liu, Z; Lu, X; Pannecouque, C; Yang, J; Zhan, P1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Buckheit, RW; Cushman, M; Hartman, TL; Hoshi, A; Okazaki, M; Pannecouque, C; Sakamoto, T; Takayama, J; Xuan, M1
Chen, W; Daelemans, D; De Clercq, E; Huang, B; Liu, X; Pannecouque, C; Yang, J; Zhan, P1
Daelemans, D; De Clercq, E; Huang, B; Kang, D; Li, X; Liu, X; Lu, X; Pannecouque, C; Yang, J; Zhan, P; Zhao, F; Zhou, Z1
Daelemans, D; De Clercq, E; Ding, X; Fang, Z; Huang, B; Kang, D; Li, Z; Liu, X; Lu, X; Pannecouque, C; Xu, H; Zhan, P; Zhang, H; Zhou, Z1
Gu, SX; Ju, XL; Li, TT; Lu, HH; Pannecouque, C; Xiao, T; Xue, P; Zhang, X; Zheng, XJ; Zhu, YY1
Chen, CH; Daelemans, D; De Clercq, E; Huang, B; Kang, D; Lee, KH; Liu, J; Liu, X; Liu, Z; Pannecouque, C; Tian, Y; Zhan, P; Zhang, H1
Byrareddy, SN; Kongsted, J; Kramer, VG; Kurup, S; Liu, X; Namasivayam, V; Vanangamudi, M; Zhan, P1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Bender, R; Kirsch, R; Kleim, JP; Meichsner, C; Paessens, A; Riess, G1
Evans, DB; Fan, N; Rank, KB; Sharma, SK; Tarpley, WG; Thomas, RC1
Chen, IS; Dueweke, TJ; Poppe, SM; Pushkarskaya, T; Stevenson, M; Swaney, SM; Tarpley, WG; Zhao, JQ1
Arts, EJ; Gu, Z; Li, Z; Quan, Y; Wainberg, MA1
Gu, Z; Li, X; Parniak, MA; Quan, Y; Wainberg, MA1
Boucher, CA; Miller, V; Phair, JP; Staszewski, S1
Coleman, RL; Holtzer, CD1
Balzarini, J; De Clercq, E; Kleim, JP; Pelemans, H; Riess, G; Roesner, M; Winkler, I1
De Clercq, E1
Saag, MS; Schooley, RT1
Ekstrand, DH; Gronowitz, JS; Källander, CF; Rytting, AS; Shao, X; Vrang, L1
Roca, B; Simón, E1
Crowe, S1
Temesgen, Z; Wright, AJ1
Clotet, B1
Arnó, A; Blazquez, J; Bloor, S; Bonjoch, A; Casado, JL; Clotet, B; Dronda, F; Garcia-Arata, I; Hertogs, K; Larder, B; Ruiz, L; Van Cauwenberge, A1
Balzarini, J; Burt, V; Carbonez, A; De Clercq, E; Kleim, JP1
Conway, B1
Daily, JP; Duan, SX; Giancarlo, GM; Granda, BW; Greenblatt, DJ; Harmatz, JS; Shader, RI; von Moltke, LL1
Deeks, SG1
Bacheler, L; Baker, D; Buckery, R; Cordova, B; D'Aquila, R; Gallagher, K; Hanna, G; Hertogs, K; Jeffrey, S; Larder, B; Logue, K; Rizzo, C; Scarnati, H; Tritch, R; Wallace, L1
Bowers, M1
Bartlett, JG1
Cadman, J1
Adachi, A; Fujiwara, T; Hayami, M; Isaka, Y; Kawauchi, S; Miki, S; Miura, T; Sato, A; Sugimoto, H; Suyama, A; Yoshie, O1
Bartoli, A; Feroggio, M; Gianelli, L; Maserati, R; Montagna, M; Regazzi, MB; Villani, P1
DiCenzo, R; Morse, GD; Smith, PF1
Campiani, G; Catalanotti, B; Fattorusso, C; Maga, G; Morelli, E; Nacci, V; Novellino, E; Ramunno, A1
Kashuba, AD; Rezk, NL; Tidwell, RR1
Greenblatt, DJ; Perloff, MD; Störmer, E; von Moltke, LL1
Antela, A; Casado, JL; Dronda, F; Gutiérrez, C; Moreno, A; Moreno, S; Pérez-Elías, MJ1
Dieterich, DT; Kontorinis, N1
Moyle, GJ1
de la Rosa, R; Heath, KV; Hogg, RS; Lee, N; Montaner, JS; O'Shaughnessy, MV; Wood, E; Yip, B1
Hamatake, R; Hong, Z; Zhang, Z1
Xie, L; Zhou, T1
Boeri, E; Castagna, A; Gallotta, G; Gianotti, N; Maillard, M; Ratti, D; Serra, G; Tremolada, Y; Vacchini, D1
Eshleman, SH; Galovich, J; Jackson, JB; Jones, D; Parkin, N; Paxinos, EE; Petropoulos, CJ1
Bosch, RJ; Clark, SA; Mellors, JW; Shulman, NS1
Danielson, UH; Geitmann, M; Unge, T1
Gangakhedkar, RR; Hayatnagarkar, SS; Kurle, SN; Paranjape, RS; Sen, S; Tripathy, SP1
Anderson, KS; Radzio, J; Sluis-Cremer, N; Xia, Q1
Barnard, RJ; Felock, P; Hazuda, DJ; Lai, MT; Lu, M; Miller, MD; Munshi, V1
Cheng, J; Han, N; Liu, YN; Liu, ZY; Wei, HS; Zhang, FJ; Zhao, HX; Zhao, Y1
Ambrose, Z; Herman, BD; Moore, KL; Nissley, DV; Sheen, CW; Sluis-Cremer, N; Tachedjian, G; Zelina, S1
Cao, YL; Chen, H; Guo, Y; Li, SX1
Ariën, KK; Heyndrickx, L; Michiels, J; Quiñones-Mateu, ME; Selhorst, P; Terrazas-Aranda, K; Vanham, G; Vazquez, AC; Vereecken, K; Weber, J1
Debyser, Z; Desimmie, BA; Schrijvers, R1
Balakrishnan, P; Iqbal, HS; Kumarasamy, N; Saravanan, S; Solomon, S; Solomon, SS; Vidya, M1
Colby-Germinario, SP; Han, Y; Huang, W; Oliveira, M; Petropoulos, CJ; Quan, Y; Wainberg, MA; Xu, HT1
Cavadas, C; Costa, S; do Céu Sousa, M; Machado, M1
Andreoni, M; Antinori, A; Bagnarelli, P; Borghi, V; Bruzzone, B; Callegaro, AP; De Gennaro, M; Gianotti, N; Maffongelli, G; Maggiolo, F; Saladini, F; Sterrantino, G; Vergori, A; Zaccarelli, M; Zazzi, M1

Reviews

17 review(s) available for delavirdine and nevirapine

ArticleYear
From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Journal of medicinal chemistry, 2005, Mar-24, Volume: 48, Issue:6

    Topics: Anti-HIV Agents; Benzodiazepines; Drug Design; Drug Resistance, Viral; HIV Reverse Transcriptase; Imidazoles; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors

2005
Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors from arylthioacetanilide structural motif.
    European journal of medicinal chemistry, 2015, Sep-18, Volume: 102

    Topics: Acetanilides; Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Discovery; HIV Reverse Transcriptase; HIV-1; Hydrogen Bonding; Microbial Sensitivity Tests; Molecular Structure; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2015
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Clinical experience with non-nucleoside reverse transcriptase inhibitors.
    AIDS (London, England), 1997, Volume: 11 Suppl A

    Topics: Acetamides; Acetophenones; Animals; Anti-HIV Agents; Delavirdine; HIV; HIV Infections; Nevirapine; Nucleosides; Reverse Transcriptase Inhibitors

1997
Use of nonnucleoside reverse-transcriptase inhibitors.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1998, Feb-01, Volume: 55, Issue:3

    Topics: Anti-HIV Agents; Delavirdine; Drug Interactions; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors

1998
The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
    Antiviral research, 1998, Volume: 38, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Virus Replication

1998
Antiretroviral chemotherapy.
    Current clinical topics in infectious diseases, 1998, Volume: 18

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine

1998
New reverse transcriptase inhibitors.
    Advances in experimental medicine and biology, 1999, Volume: 458

    Topics: Adenine; Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Dideoxynucleosides; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Organophosphonates; Oxazines; Prodrugs; Reverse Transcriptase Inhibitors; Soman; Uracil

1999
Antiretrovirals.
    Mayo Clinic proceedings, 1999, Volume: 74, Issue:12

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine

1999
Efavirenz: resistance and cross-resistance.
    International journal of clinical practice. Supplement, 1999, Volume: 103

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Microbial; Genotype; HIV Infections; HIV-1; Humans; Mutation; Nevirapine; Oxazines; Phenotype; Reverse Transcriptase Inhibitors; Treatment Failure; Virus Replication

1999
International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance.
    Journal of acquired immune deficiency syndromes (1999), 2001, Mar-01, Volume: 26 Suppl 1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Delavirdine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Oxazines; Phylogeny; Point Mutation; Protein Conformation; Reverse Transcriptase Inhibitors; Virus Replication

2001
Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.
    Clinical pharmacokinetics, 2001, Volume: 40, Issue:12

    Topics: Alkynes; Benzoxazines; Biological Availability; Cyclopropanes; Delavirdine; Drug Interactions; Female; Half-Life; HIV Infections; Humans; Intestinal Absorption; Male; Nevirapine; Oxazines; Pregnancy; Reverse Transcriptase Inhibitors

2001
Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives.
    Current pharmaceutical design, 2002, Volume: 8, Issue:8

    Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzodiazepinones; Benzoxazines; Cyclopropanes; Delavirdine; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Viral; Drug Therapy, Combination; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Structure; Nevirapine; Nucleosides; Oxazines; Reverse Transcriptase Inhibitors; Spiro Compounds; Thymidine; Uridine

2002
Toxicity of non-nucleoside analogue reverse transcriptase inhibitors.
    Seminars in liver disease, 2003, Volume: 23, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Delavirdine; HIV Infections; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors

2003
Protease inhibitor-sparing regimens: new evidence strengthens position.
    Journal of acquired immune deficiency syndromes (1999), 2003, Jun-01, Volume: 33 Suppl 1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Protocols; Clinical Trials as Topic; Cohort Studies; Cyclopropanes; Delavirdine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Immunosuppression Therapy; Mutation; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Viral Load

2003
Clinical utility of current NNRTIs and perspectives of new agents in this class under development.
    Antiviral chemistry & chemotherapy, 2004, Volume: 15, Issue:3

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors

2004
[Progress in HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs)].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2004, Volume: 39, Issue:8

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Coumarins; Cyclopropanes; Delavirdine; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Conformation; Molecular Structure; Nevirapine; Oxazines; Pyranocoumarins; Reverse Transcriptase Inhibitors

2004

Other Studies

110 other study(ies) available for delavirdine and nevirapine

ArticleYear
Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]pi
    Journal of medicinal chemistry, 1993, May-14, Volume: 36, Issue:10

    Topics: Antiviral Agents; Delavirdine; Indoles; Piperazines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Virus Replication

1993
Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors.
    Journal of medicinal chemistry, 1996, Sep-13, Volume: 39, Issue:19

    Topics: Animals; Anti-HIV Agents; Biological Availability; Cell Line; Delavirdine; Drug Resistance, Microbial; Drug Stability; HIV Reverse Transcriptase; HIV-1; Indoles; Molecular Structure; Piperazines; Piperidines; Pyridines; Rats; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

1996
Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8-Aryloxymethyl- and 8-arylthiomethyldipyridodiazepinones.
    Journal of medicinal chemistry, 1998, Jul-30, Volume: 41, Issue:16

    Topics: Animals; Antiviral Agents; Azepines; Biological Availability; Cell Line, Transformed; Cell Survival; Drug Evaluation, Preclinical; Drug Resistance, Microbial; Drug Stability; HIV Reverse Transcriptase; HIV-1; Humans; In Vitro Techniques; Male; Microsomes, Liver; Mutation; Nevirapine; Pyridines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Virus Replication

1998
Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.
    Bioorganic & medicinal chemistry letters, 1999, Jun-07, Volume: 9, Issue:11

    Topics: Anti-HIV Agents; Delavirdine; Drug Design; Humans; Inhibitory Concentration 50; Kinetics; Models, Molecular; Nevirapine; Pyridines; Thiourea

1999
N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
    Bioorganic & medicinal chemistry letters, 1999, Sep-20, Volume: 9, Issue:18

    Topics: Aminopyridines; Anti-HIV Agents; Drug Resistance, Microbial; Drug Resistance, Multiple; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Reverse Transcriptase Inhibitors; Thiourea

1999
Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
    Journal of medicinal chemistry, 1999, Oct-07, Volume: 42, Issue:20

    Topics: Administration, Oral; Aminopyridines; Animals; Anti-HIV Agents; Biological Availability; Crystallography, X-Ray; Drug Resistance, Microbial; HIV-1; Injections, Intravenous; Male; Models, Molecular; Molecular Conformation; Rats; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship; Urea

1999
N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
    Bioorganic & medicinal chemistry letters, 1999, Dec-20, Volume: 9, Issue:24

    Topics: Anti-HIV Agents; Cells, Cultured; HIV-1; Humans; Microbial Sensitivity Tests; Models, Molecular; Pyridines; Reverse Transcriptase Inhibitors; Thiourea; Virus Replication

1999
1-[2-(Diphenylmethoxy)ethyl]-2-methyl-5-nitroimidazole: a potent lead for the design of novel NNRTIs.
    Bioorganic & medicinal chemistry letters, 2000, Feb-07, Volume: 10, Issue:3

    Topics: Anti-HIV Agents; Cell Line; Nitroimidazoles; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2000
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
    Journal of medicinal chemistry, 2000, May-18, Volume: 43, Issue:10

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Blood Proteins; Cyclopropanes; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Structure; Mutation; Oxazines; Protein Binding; Quinazolines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Virus Replication

2000
Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
    Bioorganic & medicinal chemistry letters, 2000, Sep-18, Volume: 10, Issue:18

    Topics: Anti-HIV Agents; Cell Culture Techniques; Drug Resistance, Multiple; HIV-1; Humans; Inhibitory Concentration 50; Leukocytes, Mononuclear; Models, Molecular; Pyridines; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship; Thiourea

2000
Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
    Bioorganic & medicinal chemistry letters, 2001, Sep-03, Volume: 11, Issue:17

    Topics: Anti-HIV Agents; Drug Evaluation, Preclinical; HIV Reverse Transcriptase; HIV-1; Inhibitory Concentration 50; Mutation; Nitriles; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2001
3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Bioorganic & medicinal chemistry letters, 2003, Dec-15, Volume: 13, Issue:24

    Topics: HIV-1; Models, Molecular; Molecular Conformation; Pyridones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2003
Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
    Journal of medicinal chemistry, 2004, Feb-26, Volume: 47, Issue:5

    Topics: Anti-HIV Agents; Benzophenones; Cell Line; Crystallography, X-Ray; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Inhibitory Concentration 50; Mutation; Protein Binding; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2004
Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 varian
    Journal of medicinal chemistry, 2004, May-06, Volume: 47, Issue:10

    Topics: Anti-HIV Agents; Crystallography, X-Ray; Drug Resistance, Viral; HIV Reverse Transcriptase; Models, Molecular; Mutation; Nitriles; Protein Conformation; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors

2004
Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
    Journal of medicinal chemistry, 2004, Nov-18, Volume: 47, Issue:24

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Binding Sites; Cell Line; Crystallography, X-Ray; Cyclopropanes; Drug Design; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Structure; Mutation; Oxazines; Quinolones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2004
Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
    Journal of medicinal chemistry, 2005, Mar-24, Volume: 48, Issue:6

    Topics: Anti-HIV Agents; Cell Line; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Pyrimidines; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship

2005
Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA.
    Journal of medicinal chemistry, 2005, Apr-07, Volume: 48, Issue:7

    Topics: Allosteric Site; Anti-HIV Agents; Crystallography, X-Ray; Databases, Factual; Drug Design; HIV Reverse Transcriptase; Models, Molecular; Molecular Conformation; Molecular Structure; Protein Binding; Quantitative Structure-Activity Relationship; Reverse Transcriptase Inhibitors; Statistics as Topic; Thermodynamics

2005
Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
    Drug metabolism and disposition: the biological fate of chemicals, 2007, Volume: 35, Issue:3

    Topics: Animals; Anti-HIV Agents; Cell Line; Dogs; Humans; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Reverse Transcriptase Inhibitors

2007
Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
    European journal of medicinal chemistry, 2007, Volume: 42, Issue:5

    Topics: Animals; Chromatography, High Pressure Liquid; Dogs; Female; HIV-1; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Nitriles; Pyrimidines; Rats; Rats, Wistar; Reverse Transcriptase Inhibitors; Rilpivirine; Spectrophotometry, Ultraviolet

2007
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Molecular characteristics for solid-state limited solubility.
    Journal of medicinal chemistry, 2008, May-22, Volume: 51, Issue:10

    Topics: Chemical Phenomena; Chemistry, Physical; Molecular Structure; Multivariate Analysis; Pharmaceutical Preparations; Regression Analysis; Solubility

2008
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Journal of medicinal chemistry, 2008, Aug-28, Volume: 51, Issue:16

    Topics: Alkynes; Amino Acid Substitution; Benzophenones; Benzoxazines; Crystallography, X-Ray; Cyclopropanes; Drug Design; Drug Resistance, Viral; HIV Reverse Transcriptase; Models, Molecular; Nevirapine; Nitriles; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Sulfonamides

2008
1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Bioorganic & medicinal chemistry letters, 2008, Oct-15, Volume: 18, Issue:20

    Topics: Anti-HIV Agents; Biological Assay; Cell Line; Chemistry, Pharmaceutical; Drug Design; Drug Evaluation, Preclinical; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Chemical; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thiadiazoles; Virus Replication

2008
Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:2

    Topics: Anti-HIV Agents; Cells, Cultured; Cervix Uteri; Dose-Response Relationship, Drug; Female; HIV Infections; HIV-1; Humans; Luciferases; Macrophages; Organ Culture Techniques; Pyrimidines; Reverse Transcriptase Inhibitors; T-Lymphocytes

2009
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
    Bioorganic & medicinal chemistry, 2009, Jan-15, Volume: 17, Issue:2

    Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship

2009
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:5

    Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Nucleosides; Phenotype; Reverse Transcriptase Inhibitors

2009
Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:11

    Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Models, Molecular; Protein Binding; Structure-Activity Relationship

2009
Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Bioorganic & medicinal chemistry, 2009, Aug-15, Volume: 17, Issue:16

    Topics: Acetanilides; Anti-HIV Agents; Binding Sites; Computer Simulation; HIV Reverse Transcriptase; Humans; Imidazoles; Structure-Activity Relationship

2009
Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5

    Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutagenesis, Site-Directed; Mutation; Nucleosides; Phenotype; pol Gene Products, Human Immunodeficiency Virus; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Virus Replication

2010
Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV.
    Bioorganic & medicinal chemistry, 2010, Apr-01, Volume: 18, Issue:7

    Topics: Anti-HIV Agents; Cell Line; Cell Survival; HIV-1; HIV-2; Humans; Indicators and Reagents; Pyrimidines; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship

2010
Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors.
    Bioorganic & medicinal chemistry, 2010, Jul-01, Volume: 18, Issue:13

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Binding Sites; Cell Line; Computer Simulation; Cyclopropanes; HIV Reverse Transcriptase; HIV-1; Humans; Naphthols; Pyrimidines; Reverse Transcriptase Inhibitors

2010
Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
    Bioorganic & medicinal chemistry, 2010, Jul-15, Volume: 18, Issue:14

    Topics: Anti-HIV Agents; Cell Line; Cell Survival; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Nitriles; Protein Binding; Pyridazines; Pyrimidines; Quinazolines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2010
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:10

    Topics: Cell Line; Cell Line, Tumor; Crystallography, X-Ray; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutagenesis, Site-Directed; Nitriles; Pyrazoles; Reverse Transcriptase Inhibitors

2010
Interaction potential of etravirine with drug transporters assessed in vitro.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:3

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Dogs; Humans; Neoplasm Proteins; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors

2011
Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Bioorganic & medicinal chemistry, 2011, Jul-15, Volume: 19, Issue:14

    Topics: Anti-HIV Agents; Cell Line, Tumor; Crystallography, X-Ray; Dose-Response Relationship, Drug; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyrimidinones; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship; Virus Replication

2011
Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.
    Bioorganic & medicinal chemistry, 2011, Sep-01, Volume: 19, Issue:17

    Topics: Aniline Compounds; Cell Line; Chlorine; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2011
Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.
    Bioorganic & medicinal chemistry, 2011, Dec-01, Volume: 19, Issue:23

    Topics: Anti-HIV Agents; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2011
Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors.
    European journal of medicinal chemistry, 2012, Volume: 53

    Topics: HIV Reverse Transcriptase; HIV-1; HIV-2; Models, Molecular; Protein Conformation; Pyrimidines; Reverse Transcriptase Inhibitors; Stereoisomerism

2012
Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.
    Bioorganic & medicinal chemistry, 2012, Sep-15, Volume: 20, Issue:18

    Topics: Acetanilides; Anti-HIV Agents; Cell Line; Dose-Response Relationship, Drug; Drug Design; HIV-1; Humans; Imidazoles; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Virus Replication

2012
Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
    Bioorganic & medicinal chemistry letters, 2012, Dec-01, Volume: 22, Issue:23

    Topics: Binding Sites; Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thioglycolates; Triazines

2012
Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
    Bioorganic & medicinal chemistry, 2012, Dec-01, Volume: 20, Issue:23

    Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Structure-Activity Relationship; Thioacetamide

2012
Synthesis, biological evaluation and molecular modeling of 4,6-diarylpyrimidines and diarylbenzenes as novel non-nucleosides HIV-1 reverse transcriptase inhibitors.
    European journal of medicinal chemistry, 2012, Volume: 58

    Topics: Anti-HIV Agents; Antineoplastic Agents; Benzene Derivatives; Cell Survival; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Models, Molecular; Molecular Structure; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured

2012
Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.
    Bioorganic & medicinal chemistry, 2013, Apr-01, Volume: 21, Issue:7

    Topics: Cell Line; Delavirdine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Pyridazines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2013
Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    European journal of medicinal chemistry, 2013, Volume: 65

    Topics: Anti-HIV Agents; Benzophenones; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2013
Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
    Bioorganic & medicinal chemistry, 2013, Nov-01, Volume: 21, Issue:21

    Topics: Binding Sites; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Protein Binding; Protein Structure, Tertiary; Pyrimidines; Pyrimidinones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2013
Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.
    Bioorganic & medicinal chemistry, 2014, Jan-01, Volume: 22, Issue:1

    Topics: Aniline Compounds; Anti-HIV Agents; Drug Design; HIV-1; Humans; Models, Molecular; Piperidines; Structure-Activity Relationship

2014
Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.
    Bioorganic & medicinal chemistry, 2014, Mar-15, Volume: 22, Issue:6

    Topics: Anti-HIV Agents; Crystallization; Dose-Response Relationship, Drug; Drug Discovery; HIV Reverse Transcriptase; HIV-1; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyridones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2014
Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach.
    European journal of medicinal chemistry, 2014, Apr-09, Volume: 76

    Topics: Cell Line; Drug Discovery; HIV Reverse Transcriptase; HIV-1; Humans; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Pyridines; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship; Virus Replication

2014
Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives.
    Bioorganic & medicinal chemistry, 2014, Apr-01, Volume: 22, Issue:7

    Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; Heterocyclic Compounds; HIV; HIV Reverse Transcriptase; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Nitrogen; Pyrazoles; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2014
Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Bioorganic & medicinal chemistry, 2014, Apr-15, Volume: 22, Issue:8

    Topics: Binding Sites; Cell Line; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Protein Structure, Tertiary; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2014
Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Bioorganic & medicinal chemistry, 2014, Jun-15, Volume: 22, Issue:12

    Topics: Anti-HIV Agents; Benzamides; Cell Survival; Cells, Cultured; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Nitriles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured; Virus Replication

2014
Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
    European journal of medicinal chemistry, 2014, Jul-23, Volume: 82

    Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; HIV-2; Microbial Sensitivity Tests; Molecular Structure; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2014
Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach.
    European journal of medicinal chemistry, 2014, Oct-06, Volume: 85

    Topics: Drug Design; HIV Reverse Transcriptase; HIV-1; Models, Molecular; Mutation; Nitrogen; Protein Conformation; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2014
Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors.
    Bioorganic & medicinal chemistry, 2014, Oct-01, Volume: 22, Issue:19

    Topics: Acetanilides; Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; HIV-1; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyrimidines; Structure-Activity Relationship; Virus Replication

2014
From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
    Bioorganic & medicinal chemistry, 2014, Oct-01, Volume: 22, Issue:19

    Topics: Anti-HIV Agents; Cell Line; Cell Survival; Dose-Response Relationship, Drug; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Parasitic Sensitivity Tests; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosoma brucei rhodesiense

2014
Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Bioorganic & medicinal chemistry, 2015, Feb-01, Volume: 23, Issue:3

    Topics: Anti-HIV Agents; Binding Sites; Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2015
Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
    European journal of medicinal chemistry, 2015, Jun-05, Volume: 97

    Topics: Anti-HIV Agents; Cells, Cultured; Drug Discovery; HIV Reverse Transcriptase; Humans; Molecular Structure; Nitriles; Piperidines; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2015
Hybrid chemistry. Part 4: Discovery of etravirine-VRX-480773 hybrids as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Bioorganic & medicinal chemistry, 2015, Aug-01, Volume: 23, Issue:15

    Topics: Acetanilides; Anti-HIV Agents; Cell Line; Chemistry Techniques, Synthetic; Drug Discovery; Drug Evaluation, Preclinical; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Dynamics Simulation; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazoles

2015
Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
    European journal of medicinal chemistry, 2016, Feb-15, Volume: 109

    Topics: Anti-HIV Agents; Binding Sites; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Point Mutation; Pyridines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2016
Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
    Bioorganic & medicinal chemistry, 2016, 07-01, Volume: 24, Issue:13

    Topics: Anti-HIV Agents; Drug Stability; Esters; HIV-1; Humans; Inhibitory Concentration 50; Methane; Models, Molecular; Reverse Transcriptase Inhibitors

2016
Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.
    European journal of medicinal chemistry, 2016, Oct-04, Volume: 121

    Topics: Binding Sites; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; Molecular Docking Simulation; Protein Conformation; Pyridines; Pyrimidines; Reverse Transcriptase Inhibitors; Solubility; Structure-Activity Relationship; Water

2016
Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
    Bioorganic & medicinal chemistry, 2016, 09-15, Volume: 24, Issue:18

    Topics: Acetanilides; Anti-HIV Agents; Carbon-13 Magnetic Resonance Spectroscopy; HIV-1; Models, Molecular; Proton Magnetic Resonance Spectroscopy; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship

2016
Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
    Journal of medicinal chemistry, 2016, 09-08, Volume: 59, Issue:17

    Topics: Animals; Anti-HIV Agents; Cell Line, Tumor; Drug Resistance, Viral; Heterocyclic Compounds, 2-Ring; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mice; Molecular Docking Simulation; Mutation; Pyrimidines; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Sulfonamides; Thiophenes

2016
Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: Synthesis, anti-HIV activities and SAR.
    Bioorganic & medicinal chemistry, 2017, 04-15, Volume: 25, Issue:8

    Topics: Anti-HIV Agents; Carbon-13 Magnetic Resonance Spectroscopy; HIV-1; Molecular Docking Simulation; Proton Magnetic Resonance Spectroscopy; Pyrimidines; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Electrospray Ionization

2017
Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
    European journal of medicinal chemistry, 2018, May-10, Volume: 151

    Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Niacinamide; Point Mutation; Structure-Activity Relationship; Triazoles

2018
The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
    Journal of medicinal chemistry, 2019, 05-23, Volume: 62, Issue:10

    Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Drug Discovery; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors

2019
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023
Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase.
    Virology, 1994, May-01, Volume: 200, Issue:2

    Topics: Antiviral Agents; Base Sequence; Benzodiazepines; Benzoxazoles; Delavirdine; DNA Mutational Analysis; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Imidazoles; Indoles; Molecular Sequence Data; Mutagenesis, Site-Directed; Nevirapine; Piperazines; Pyridines; Pyridones; Quinoxalines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Selection, Genetic; Structure-Activity Relationship

1994
Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s.
    FEBS letters, 1995, Aug-14, Volume: 370, Issue:1-2

    Topics: Amino Acid Sequence; Antiviral Agents; Benzodiazepines; Benzoxazoles; Cloning, Molecular; Delavirdine; HIV Reverse Transcriptase; HIV-1; HIV-2; Imidazoles; Indoles; Kinetics; Molecular Sequence Data; Mutagenesis, Site-Directed; Nevirapine; Piperazines; Point Mutation; Pyridines; Pyridones; Recombinant Fusion Proteins; Recombinant Proteins; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tyrosine

1995
A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.
    Proceedings of the National Academy of Sciences of the United States of America, 1993, May-15, Volume: 90, Issue:10

    Topics: Antiviral Agents; Base Sequence; Benzodiazepines; Benzoxazoles; Cloning, Molecular; Delavirdine; Drug Resistance; HIV Reverse Transcriptase; Imidazoles; Indoles; Molecular Sequence Data; Mutation; Nevirapine; Oligodeoxyribonucleotides; Piperazines; Pyridines; Pyridones; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase

1993
Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays.
    The Journal of biological chemistry, 1995, Dec-29, Volume: 270, Issue:52

    Topics: Cell-Free System; Delavirdine; Deoxycytosine Nucleotides; Dideoxynucleotides; Drug Antagonism; Drug Synergism; HIV Reverse Transcriptase; HIV-1; Indoles; Nevirapine; Piperazines; Pyridines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Thymine Nucleotides; Zidovudine

1995
Studies of neutralizing monoclonal antibody to human immunodeficiency virus type 1 reverse transcriptase: antagonistic and synergistic effects in reactions performed in the presence of nucleoside and nonnucleoside inhibitors, respectively.
    Journal of virology, 1996, Volume: 70, Issue:4

    Topics: Animals; Antibodies, Monoclonal; Antiviral Agents; Delavirdine; Deoxycytosine Nucleotides; Dideoxynucleotides; DNA; HIV Antibodies; HIV Reverse Transcriptase; Humans; Indoles; Mice; Neutralization Tests; Nevirapine; Peptide Chain Elongation, Translational; Piperazines; Pyridines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Thymine Nucleotides; Zidovudine

1996
Drugs for HIV infection.
    The Medical letter on drugs and therapeutics, 1997, Dec-12, Volume: 39, Issue:1015

    Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Virus Replication; Zalcitabine; Zidovudine

1997
Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined
    Biochemical pharmacology, 1998, Mar-01, Volume: 55, Issue:5

    Topics: Anti-HIV Agents; Antiviral Agents; Benzodiazepines; Cell Line; Delavirdine; Drug Resistance, Microbial; Furans; HIV Reverse Transcriptase; HIV-1; Humans; Imidazoles; Lamivudine; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Mutation; Nevirapine; Quinoxalines; Recombinant Proteins; Reverse Transcriptase Inhibitors; Zidovudine

1998
Colorimetric assays for evaluation of the mode of action of human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors.
    Antiviral chemistry & chemotherapy, 1998, Volume: 9, Issue:2

    Topics: Amino Acid Sequence; Anti-HIV Agents; Benzodiazepines; Colorimetry; Delavirdine; Drug Evaluation; Enzyme-Linked Immunosorbent Assay; HIV Reverse Transcriptase; HIV-1; Imidazoles; Molecular Sequence Data; Nevirapine; Pyridines; Recombinant Proteins; Reverse Transcriptase Inhibitors; Templates, Genetic; Thiourea

1998
[Non-nucleoside reverse transcriptase inhibitors of the human immunodeficiency virus].
    Medicina clinica, 1998, Nov-21, Volume: 111, Issue:17

    Topics: Anti-HIV Agents; Delavirdine; Humans; Nevirapine; Reverse Transcriptase Inhibitors

1998
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.
    AIDS (London, England), 2000, Jan-28, Volume: 14, Issue:2

    Topics: Adult; Alkynes; Benzoxazines; Cohort Studies; Cyclopropanes; Delavirdine; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Hospitals, University; Humans; Male; Middle Aged; Mutation; Nevirapine; Oxazines; Protease Inhibitors; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Viral Load

2000
Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
    AIDS research and human retroviruses, 2000, Apr-10, Volume: 16, Issue:6

    Topics: Alkynes; Anilides; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Delavirdine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Microbial; Furans; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Mutation; Nevirapine; Oxazines; Quinoxalines; Reverse Transcriptase Inhibitors; Thioamides; Uracil

2000
Initial therapy with protease inhibitor-sparing regimens: evaluation of nevirapine and delavirdine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2000, Volume: 30 Suppl 2

    Topics: Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nevirapine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Outcome

2000
Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.
    Journal of clinical pharmacology, 2001, Volume: 41, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Delavirdine; Humans; Hydrolysis; Inhibitory Concentration 50; Isoenzymes; Microsomes, Liver; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Triazolam

2001
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Journal of virology, 2001, Volume: 75, Issue:11

    Topics: Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Cells, Cultured; Clinical Trials, Phase II as Topic; Cohort Studies; Cyclopropanes; Delavirdine; Drug Resistance, Microbial; Drug Resistance, Multiple; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Leukocytes, Mononuclear; Microbial Sensitivity Tests; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Treatment Failure

2001
Non-nucleoside reverse transcriptase inhibitors.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1996

    Topics: Acetamides; Acetophenones; Antiviral Agents; Delavirdine; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Indoles; Nevirapine; Piperazines; Pyridines; Reverse Transcriptase Inhibitors

1996
Nevirapine and delavirdine plus protease inhibitors.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1996, Volume: 10, Issue:4

    Topics: Delavirdine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indoles; Nevirapine; Piperazines; Pyridines; Reverse Transcriptase Inhibitors

1996
Late breaking news: two additional DHHS guidelines changes. Department of Health and Human Services.
    The Hopkins HIV report : a bimonthly newsletter for healthcare providers, 1998, Volume: 10, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Delavirdine; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors

1998
NNRTIs: a neglected class.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1998, Volume: 12, Issue:9

    Topics: Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Delavirdine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors

1998
Strategy update: protease-sparing regimens.
    Project Inform perspective, 1998, Issue:26

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors

1998
Antivirals update.
    Project Inform perspective, 1998, Issue:26

    Topics: Anti-HIV Agents; Carbamates; Delavirdine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nevirapine; Reverse Transcriptase Inhibitors; Salvage Therapy; Sulfonamides

1998
A single amino acid change at Leu-188 in the reverse transcriptase of HIV-2 and SIV renders them sensitive to non-nucleoside reverse transcriptase inhibitors.
    Archives of virology, 2001, Volume: 146, Issue:4

    Topics: Alkynes; Amino Acid Sequence; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Delavirdine; Drug Resistance, Microbial; HeLa Cells; HIV Reverse Transcriptase; HIV-2; Humans; Leucine; Molecular Sequence Data; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Sequence Homology, Amino Acid; Simian Immunodeficiency Virus; Species Specificity

2001
Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay.
    Therapeutic drug monitoring, 2001, Volume: 23, Issue:4

    Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, Liquid; Cyclopropanes; Delavirdine; Drug Monitoring; Furans; HIV Protease Inhibitors; Humans; Indinavir; Mass Spectrometry; Nelfinavir; Nevirapine; Oxazines; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides

2001
Drugs for HIV infection.
    The Medical letter on drugs and therapeutics, 2001, Nov-26, Volume: 43, Issue:1119

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dose-Response Relationship, Drug; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Saquinavir; Stavudine; Zidovudine

2001
Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet absorbance detection.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2002, Jul-05, Volume: 774, Issue:1

    Topics: Alkynes; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Delavirdine; HIV Infections; HIV-1; Humans; Nevirapine; Oxazines; Reference Standards; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Spectrophotometry, Ultraviolet

2002
Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture.
    Pharmaceutical research, 2002, Volume: 19, Issue:7

    Topics: Alkynes; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; Caco-2 Cells; Cyclopropanes; Delavirdine; Dose-Response Relationship, Drug; HIV Reverse Transcriptase; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Tumor Cells, Cultured

2002
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1.
    AIDS (London, England), 2003, Jun-13, Volume: 17, Issue:9

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors

2003
Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.
    AIDS (London, England), 2003, Dec-05, Volume: 17, Issue:18

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Delavirdine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nevirapine; Oxazines; Prejudice; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome

2003
In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results.
    The new microbiologica, 2004, Volume: 27, Issue:2 Suppl 1

    Topics: Alkynes; Amino Acid Substitution; Base Sequence; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Delavirdine; DNA, Complementary; Drug Resistance, Viral; HIV; HIV Infections; HIV Reverse Transcriptase; Humans; Mutation; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Selection, Genetic; Viremia

2004
Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations.
    AIDS research and human retroviruses, 2006, Volume: 22, Issue:3

    Topics: Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Clone Cells; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Female; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nevirapine; Oxazines; Polymorphism, Genetic; Reverse Transcriptase Inhibitors

2006
Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors.
    AIDS (London, England), 2006, Apr-24, Volume: 20, Issue:7

    Topics: Alkynes; Benzoxazines; Codon; Cyclopropanes; Delavirdine; Drug Resistance, Viral; HIV-1; Mutation; Nevirapine; Oxazines; Phenotype; Recombination, Genetic; Reverse Transcriptase Inhibitors; Virus Replication

2006
Biosensor-based kinetic characterization of the interaction between HIV-1 reverse transcriptase and non-nucleoside inhibitors.
    Journal of medicinal chemistry, 2006, Apr-20, Volume: 49, Issue:8

    Topics: Alkynes; Benzoxazines; Binding Sites; Biosensing Techniques; Cyclopropanes; Delavirdine; Enzyme Activation; HIV Reverse Transcriptase; Kinetics; Molecular Structure; Nevirapine; Oxazines; Protein Conformation; Pyridines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Time Factors; Urea

2006
Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.
    AIDS research and human retroviruses, 2007, Volume: 23, Issue:5

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Feasibility Studies; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; India; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Molecular Sequence Data; Mutation; Nevirapine; Polymerase Chain Reaction; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors

2007
Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses.
    Protein science : a publication of the Protein Society, 2007, Volume: 16, Issue:8

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Binding Sites; Catalysis; Cyclopropanes; Delavirdine; HIV Reverse Transcriptase; Kinetics; Models, Molecular; Nevirapine; Protein Conformation; Reverse Transcriptase Inhibitors; Thymine Nucleotides

2007
Monitoring the development of non-nucleoside reverse transcriptase inhibitor-associated resistant HIV-1 using an electrochemiluminescence-based reverse transcriptase polymerase assay.
    Analytical biochemistry, 2008, Mar-01, Volume: 374, Issue:1

    Topics: Alkynes; Benzoxazines; Cell Line; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Electrochemistry; HIV-1; Humans; Luminescent Measurements; Nevirapine; Organometallic Compounds; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA-Directed DNA Polymerase

2008
[HIV-1 genotypic resistance profiles in children failing highly active antiretroviral therapy].
    Zhonghua yi xue za zhi, 2007, Dec-11, Volume: 87, Issue:46

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; China; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Genotype; HIV-1; Humans; Mutation; Nevirapine; Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Viral Load; Zidovudine

2007
The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs.
    Journal of virology, 2009, Volume: 83, Issue:8

    Topics: Adenine; Anti-HIV Agents; Delavirdine; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Kinetics; Lamivudine; Microbial Sensitivity Tests; Mutation, Missense; Nevirapine; Organophosphonates; Protein Binding; Reverse Transcriptase Inhibitors; Tenofovir

2009
[Establishment of pharmacological evaluation system for non-nucleoside reverse-transcriptase inhibitors resistant HIV-1].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2009, Volume: 44, Issue:4

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Delavirdine; Drug Evaluation, Preclinical; Drug Resistance, Viral; Genetic Vectors; HIV Reverse Transcriptase; HIV-1; Humans; Membrane Glycoproteins; Nevirapine; Plasmids; Point Mutation; Reverse Transcriptase Inhibitors; Stavudine; Transfection; Viral Envelope Proteins; Virion; Virus Replication; Zidovudine

2009
Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:4

    Topics: Alkynes; Anilides; Anti-Infective Agents; Benzoxazines; Cell Line; Cells, Cultured; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Furans; Genotype; HIV-1; Humans; Nevirapine; Reverse Transcriptase Inhibitors; Thiazoles; Thioamides; Thiourea

2011
Rilpivirine: a step forward in tailored HIV treatment.
    Lancet (London, England), 2011, Jul-16, Volume: 378, Issue:9787

    Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase III as Topic; Cyclopropanes; Delavirdine; Deoxycytidine; Drug Design; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Multicenter Studies as Topic; Mutation; Nevirapine; Nitriles; Organophosphonates; Pyrimidines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Viral Load

2011
HIV-1 drug resistance among newly HIV-1 infected individuals attending tertiary referral center in Chennai, India.
    Indian journal of medical sciences, 2011, Volume: 65, Issue:11

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; India; Nevirapine; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; Tertiary Care Centers

2011
Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:11

    Topics: Alkynes; Amino Acid Substitution; Benzoxazines; Cyclopropanes; Delavirdine; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HEK293 Cells; HIV Reverse Transcriptase; HIV-1; Humans; Leukocytes, Mononuclear; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Virus Replication

2013
Antileishmanial activity of antiretroviral drugs combined with miltefosine.
    Parasitology research, 2016, Volume: 115, Issue:10

    Topics: Alkynes; Animals; Anti-Retroviral Agents; Antiprotozoal Agents; Atazanavir Sulfate; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Delavirdine; Drug Therapy, Combination; HIV Infections; Humans; Leishmania infantum; Leishmaniasis, Visceral; Macrophages; Male; Mice, Inbred BALB C; Nevirapine; Phosphorylcholine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Tenofovir

2016
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
    International journal of antimicrobial agents, 2019, Volume: 53, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Treatment Outcome; Triazoles

2019